1-9 of 9
Alex Allepuz
Close
Sort by
Journal Articles

VAYHIT3: An Open-Label, Single-Arm, Phase II Trial to Evaluate the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (ITP) Previously Treated with at Least 1 Corticosteroid and 1 Thrombopoietin Receptor Agonist (TPO-RA)

David J Kuter, Charlotte A. Bradbury, Alex Allepuz, Nadège Pfender, Jens Haenig, Claus Nowak, Tomas Jose Gonzalez-Lopez
Journal: Blood
Blood (2023) 142 (Supplement 1): 5455.
https://doi.org/10.1182/blood-2023-180005
Published: 2023
Journal Articles

A Phase III Clinical Trial Program Investigating the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (VAYHIT1 and VAYHIT2) and Warm Autoimmune Hemolytic Anemia (VAYHIA)

Hanny Al-Samkari, Wilma Barcellini, Nichola Cooper, Waleed Ghanima, Marc Michel, Raymond SM Wong, Francesco Zaja, Fengkui Zhang, Patrick Urban, Alex Allepuz, Justyna Fronczek-Sokol, Jens Haenig, Pascal Edrich, Adam Cuker
Journal: Blood
Blood (2023) 142 (Supplement 1): 5456.
https://doi.org/10.1182/blood-2023-180647
Published: 2023
Journal Articles

Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study

Timothy Hughes, Delphine Rea, Carla Boquimpani, Yosuke Minami, Michael Mauro, Jorge E. Cortes, Jane F. Apperley, Valentín García Gutiérrez, Shruti Kapoor, Alex Allepuz, Sarah Quenet, Yifan Zhang, Andreas Hochhaus
Journal: Blood
Blood (2022) 140 (Supplement 1): 6757–6759.
https://doi.org/10.1182/blood-2022-169110
Published: 2022
Journal Articles

Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors

Torsten Dahlén, Camille C.B. Kockerols, Germano Ferreira, Peter E. Westerweel, Jiri Mayer, Alex Allepuz, David Wormser, Lillian Yau, Daniela Žácková
Journal: Blood
Blood (2022) 140 (Supplement 1): 3889–3890.
https://doi.org/10.1182/blood-2022-163151
Published: 2022
Journal Articles

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Clinical Trials & Observations
Delphine Réa, Michael J. Mauro, Carla Boquimpani, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Jane F. Apperley, Andre Abdo, Laura Maria Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Koji Sasaki, Lynette Chee, Valentin García-Gutiérrez, Jorge E. Cortes, Paola Aimone, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Andreas Hochhaus
Journal: Blood
Blood (2021) 138 (21): 2031–2041.
https://doi.org/10.1182/blood.2020009984
Published: 2021
Includes: Supplemental data
Journal Articles

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

Michael J. Mauro, Yosuke Minami, Delphine Rea, Andreas Hochhaus, Elza Lomaia, Sergey Voloshin, Anna G. Turkina, Dong-Wook Kim, Jane F Apperley, Jorge E. Cortes, Andre N.R. Abdo, Laura Fogliatto, Dennis Dong Hwan Kim, Philipp D le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem A. Chaudhri, Lynette C.Y. Chee, Valentín Garcia Gutierrez, Koji Sasaki, Shruti Kapoor, Alex Allepuz, Sarah Quenet, Véronique Bédoucha, Carla Boquimpani
Journal: Blood
Blood (2021) 138 (Supplement 1): 310.
https://doi.org/10.1182/blood-2021-152561
Published: 2021
Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Andreas Hochhaus, MD, Carla Boquimpani, MD, Delphine Rea, MDPhD, Yosuke Minami, MDPhD, Elza Lomaia, MD PhD, Sergey Voloshin, MD PhD, Anna G. Turkina, Prof., MD, Dong-Wook Kim, MD, Jane Apperley, FRCP, FRCPath, MB, Jorge E. Cortes, MD, Andre Abdo, MD, Laura Maria Fogliatto, MD PhD, Dennis Dong Hwan Kim, MD PhD, Philipp D le Coutre, MD, Susanne Saussele, MD, Mario Annunziata, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Naeem A. Chaudhri, MD, Lynette C.Y. Chee, MBBS,PhDFRACP,FRCPA, Valentín García Gutiérrez, MD PhD, Koji Sasaki, MD, Paola Aimone, MD, Alex Allepuz, MD MPH, Sarah Quenet, Véronique Bédoucha, Michael J. Mauro, MD
Journal: Blood
Blood (2020) 136 (Supplement_2): LBA-4.
https://doi.org/10.1182/blood-2020-143816
Published: 2020
Journal Articles

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Clinical Trials & Observations
Nobuko Hijiya, Alexey Maschan, Carmelo Rizzari, Hiroyuki Shimada, Carlo Dufour, Hiroaki Goto, Hyoung Jin Kang, Terri Guinipero, Zeynep Karakas, Francisco Bautista, Stéphane Ducassou, Keon Hee Yoo, Christian Michel Zwaan, Frédéric Millot, Paola Aimone, Alex Allepuz, Sara Quenet, Florence Hourcade-Potelleret, Sabine Hertle, Darintr Sosothikul
Journal: Blood
Blood (2019) 134 (23): 2036–2045.
https://doi.org/10.1182/blood.2019000069
Published: 2019
Includes: Supplemental data
Journal Articles

Benefit-Risk Comparison in Patients with Immune Thrombocytopenia (ITP) Receiving Eltrombopag or Romiplostim: Real World Evidence (RWE) from 26 Hospital Institutions

Anna Forsythe, PharmD, MSc, MBA, Anuja Roy, PhD, Menaka Bhor, PhD, Alex Allepuz, MD MPH, Maria Do Socorro Oliveira Portella, MD MBA, Christina Kwon, BSc, MSc, PhD, Gabriel Tremblay, DBA, MSc, BS
Journal: Blood
Blood (2017) 130 (Supplement 1): 3409.
https://doi.org/10.1182/blood.V130.Suppl_1.3409.3409
Published: 2017